GO
Loading...

Roche Holding AG

More

  • US STOCKS-Futures lower as weak IBM earnings weigh Monday, 20 Oct 2014 | 8:04 AM ET

    *IBM slumps after quarterly results. NEW YORK, Oct 20- U.S. stock index futures were lower on Monday, on the heels of a fourth week of losses for the benchmark S&P 500, as quarterly results from IBM disappointed. IBM shares slumped 7 percent to $169.24 as the most actively traded stock on the New York Stock Exchange in premarket after the company's third-quarter...

  • Oct 20- NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments. NewLink's shares jumped nearly 26 percent before the bell on Monday. Immunotherapies are a class of drugs designed to help the...

  • WASHINGTON, Oct 16- Medicine costs would rise if draft proposals in a Pacific Rim trade pact come into force, health and consumer rights advocates said on Thursday after the release of a leaked negotiating text. The TPP's 12 members range from the United States and Japan to Malaysia and Vietnam, where equitable access to medicine is a priority, and Australia and...

  • Swiss drug maker Roche posts flat 9-month sales Thursday, 16 Oct 2014 | 1:37 AM ET

    GENEVA— Swiss drugmaker Roche Holding AG posted flat sales for the first nine months of 2014, but said Thursday the results show strong demand for its cancer drugs and emerging new products. The Basel, Switzerland- based company's group sales were reported at 34.8 billion Swiss francs, nearly unchanged from 34.9 billion francs in the same period last year.

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...

  • Oct 15- The U.S. Food and Drug Administration approved two drugs to treat idiopathic pulmonary fibrosis, marking its first-ever approvals for the fatal lung disease with no clear etiology and no cure. Roche Holding AG's Esbriet, which is already in use in Europe and Canada, and privately held German drugmaker Boehringer Ingelheim's Ofev both received the...

  • Going in through back door for M&A deal profits Friday, 3 Oct 2014 | 8:00 AM ET

    Mergers have hit a level not seen since the financial crisis, and there is a way for investors to profit from the M&A frenzy—in one trade.

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.

  • Positive data from Roche breast cancer drug     Monday, 29 Sep 2014 | 6:25 AM ET

    A breast cancer drug from Roche known as Perjeta helped patients live nearly 16 months longer compared with Herceptin and chemotherapy alone. CNBC's Meg Tirrell provides insight to the data.

  • *Perjeta builds on Roche's strong position in breast cancer. MADRID, Sept 28- A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *Perjeta builds on Roche's strong position in breast cancer. MADRID, Sept 28- A new breast cancer drug from Roche has shown "unprecedented" survival benefits in a clinical trial, boosting prospects for its widespread use in women with an aggressive form of the disease.

  • MADRID- ROCHE'S PERJETA DRUG ADDS 15.7 MONTHS SURVIVAL BENEFIT IN METASTATIC BREAST CANCER STUDY.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.